ano3-protein

ANO3 Protein (Anoctamin 3)

<div class="infobox infobox-protein">
<div class="infobox-header">Anoctamin 3 (ANO3 / TMEM16C)</div>
<div class="infobox-row"><span class="infobox-label">Gene</span><span class="infobox-value">[ANO3](/genes/ano3) (also TMEM16C)</span></div>
<div class="infobox-row"><span class="infobox-label">UniProt</span><span class="infobox-value">[Q8N8Y2](https://www.uniprot.org/uniprot/Q8N8Y2)</span></div>
<div class="infobox-row"><span class="infobox-label">Molecular Weight</span><span class="infobox-value">102.3 kDa (913 amino acids)</span></div>
<div class="infobox-row"><span class="infobox-label">Subcellular Localization</span><span class="infobox-value">Plasma membrane, Cytoplasm, Endoplasmic reticulum</span></div>
<div class="infobox-row"><span class="infobox-label">Protein Family</span><span class="infobox-value">Anoctamin (TMEM16) family</span></div>
<div class="infobox-row"><span class="infobox-label">Expression</span><span class="infobox-value">Brain (cerebellum, basal ganglia, cortex), smooth muscle</span></div>
<div class="infobox-row"><span class="infobox-label">Diseases</span><span class="infobox-value">[Parkinson's Disease](/diseases/parkinsons-disease), Dystonia, ALS</span></div>
</div>

Overview

ANO3 Protein (Anoctamin 3)

<div class="infobox infobox-protein">
<div class="infobox-header">Anoctamin 3 (ANO3 / TMEM16C)</div>
<div class="infobox-row"><span class="infobox-label">Gene</span><span class="infobox-value">[ANO3](/genes/ano3) (also TMEM16C)</span></div>
<div class="infobox-row"><span class="infobox-label">UniProt</span><span class="infobox-value">[Q8N8Y2](https://www.uniprot.org/uniprot/Q8N8Y2)</span></div>
<div class="infobox-row"><span class="infobox-label">Molecular Weight</span><span class="infobox-value">102.3 kDa (913 amino acids)</span></div>
<div class="infobox-row"><span class="infobox-label">Subcellular Localization</span><span class="infobox-value">Plasma membrane, Cytoplasm, Endoplasmic reticulum</span></div>
<div class="infobox-row"><span class="infobox-label">Protein Family</span><span class="infobox-value">Anoctamin (TMEM16) family</span></div>
<div class="infobox-row"><span class="infobox-label">Expression</span><span class="infobox-value">Brain (cerebellum, basal ganglia, cortex), smooth muscle</span></div>
<div class="infobox-row"><span class="infobox-label">Diseases</span><span class="infobox-value">[Parkinson's Disease](/diseases/parkinsons-disease), Dystonia, ALS</span></div>
</div>

Overview

ANO3 (Anoctamin 3, also known as TMEM16C) is a member of the anoctamin family of calcium-activated chloride channels (CaCC). Initially characterized for its role in epithelial and smooth muscle physiology, ANO3 has emerged as a critical regulator of neuronal excitability in the central nervous system. Mutations in ANO3 cause Dystonia 24 (DYT24), a hereditary movement disorder characterized by involuntary muscle contractions and abnormal postures. Beyond dystonia, ANO3 is implicated in Parkinson's disease, ALS, and other neurological conditions involving altered neuronal excitability[@hartzell2009][@stogios2015].

ANO3 is highly expressed in the brain, particularly in the cerebellum, basal ganglia (striatum, globus pallidus), thalamus, and cortical regions. This distribution aligns with its role in motor control and coordination. The protein functions as a homodimer, with each subunit forming an independent chloride channel pore. Activation occurs through intracellular calcium binding, linking neuronal calcium signaling directly to chloride conductance and membrane potential modulation.

Structure

ANO3 possesses a complex architecture optimized for calcium-activated chloride conduction:

Domain Architecture

| Region | Position (AA) | Features |
|--------|--------------|----------|
| N-terminal Region | 1-200 | Cytoplasmic, contains calcium-binding sites |
| Transmembrane Domain 1-10 | 200-700 | 10 TM segments, forms channel pore |
| Porel loop | Between TM3-4 | Key selectivity filter for Cl- conductance |
| Calcium-binding Domain | Intracellular loops | Multiple EF-hand-like motifs |
| C-terminal Region | 700-913 | Regulatory domains, phosphorylation sites |

Structural Features

• Transmembrane Architecture: 10 transmembrane helices with a reentrant pore loop between TM3 and TM4, a topology shared with other TMEM16 family members
• Calcium Sensitivity: Intracellular calcium binding through multiple sites in the N-terminal and loop regions
• Dimerization: Functional channels require dimerization, with each monomer contributing to the conducting pore
• Phosphorylation: Multiple serine/threonine phosphorylation sites modulate channel activity

Normal Function

Neuronal Signaling

ANO3 regulates neuronal excitability through chloride conductance modulation:

Resting Membrane Potential

• Cl- Equilibrium: At resting potentials, ANO3 activation depolarizes neurons toward the Cl- reversal potential (approximately -70 mV in many neurons)
• Excitability Tuning: By modulating Cl- conductance, ANO3 influences action potential threshold and firing patterns
• Shunting Inhibition: Increased Cl- conductance can reduce excitatory input effectiveness through shunting

Calcium Signaling Integration

• Activity-Dependent Activation: Neuronal activity increases intracellular Ca2+, directly activating ANO3
• Negative Feedback: ANO3-mediated Cl- efflux can hyperpolarize neurons, reducing Ca2+ influx
• Signal Integration: Coordinates multiple excitatory and inhibitory inputs

Synaptic Transmission

ANO3 influences several aspects of synaptic function:

• GABAergic Signaling: Modulates inhibitory postsynaptic potentials through Cl- gradient
• Presynaptic Excitability: Alters action potential duration in terminals
• Neuromodulation: Responds to neuromodulators that increase intracellular Ca2+

Muscle Function

In non-neuronal tissues:

• Smooth Muscle: Regulates vascular tone and gastrointestinal motility
• Salivary Gland Secretion: Controls chloride secretion in exocrine glands
• Airway Epithelia: Modulates fluid and electrolyte transport

Role in Neurodegeneration

Dystonia (DYT24)

ANO3 mutations cause the first identified monogenic form of dystonia:

Genetic Basis

• Autosomal Dominant: DYT24 is inherited in an autosomal dominant pattern with incomplete penetrance
• Missense Mutations: Most disease-causing mutations are missense variants affecting channel function
• Splice Site Mutations: Some mutations affect mRNA splicing, reducing functional protein

Pathophysiology

• Loss of Function: Most ANO3 mutations reduce channel activity
• Motor Circuit Dysfunction: Altered Cl- conductance in basal ganglia disrupts movement control
• Excitability Imbalance: Reduced ANO3 function leads to hyperexcitability in affected circuits

Therapeutic Approaches

• Deep brain stimulation (DBS) of the globus pallidus internus
• Pharmacological approaches targeting other ion channels
• Gene therapy approaches under development[@margarit2014][@wang2018]

Parkinson's Disease

ANO3 is implicated in PD through several mechanisms:

Basal Ganglia Function

• Striatal Neurons: High ANO3 expression in striatal medium spiny neurons (MSNs)
• Motor Control Circuits: Alters excitability in direct and indirect pathway neurons
• Dyskinesia Link: ANO3 dysfunction may contribute to levodopa-induced dyskinesias

Genetic Association

• ANO3 variants have been associated with PD risk in GWAS
• Expression studies show altered ANO3 levels in PD brains
• Interaction with alpha-synuclein pathology[@chen2021]

Amyotrophic Lateral Sclerosis (ALS)

ANO3 contributes to motor neuron degeneration:

Hyperexcitability

• Channel Dysfunction: Reduced ANO3 function contributes to motor neuron hyperexcitability
• Excitotoxicity: Altered excitability increases vulnerability to glutamate toxicity
• Repetitive Firing: Motor neurons show abnormal firing patterns

Therapeutic Implications

• Channel Modulators: Drugs targeting Ca2+-activated Cl- channels being investigated
• Gene Therapy: AAV-mediated ANO3 expression under study[@yang2020][@catalan2019]

Epilepsy

• ANO3 dysfunction may contribute to seizure susceptibility
• Altered neuronal excitability in cortical circuits
• Interaction with other epilepsy-associated ion channels

Therapeutic Targeting

ANO3 is a potential therapeutic target for multiple neurological conditions:

Strategies

Challenges

• Tissue Specificity: Achieving brain-specific targeting vs. peripheral tissues
• Channel Kinetics: Modulating activation/deactivation rates
• Blood-Brain Barrier: Drug penetration to CNS

Clinical Trials

• No approved ANO3-targeted therapies yet
• Clinical trials for other ion channels inform development
• Biomarker development for patient selection

Key Publications

Cross-References

• [ANO3 Gene](/genes/ano3)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Dystonia](/diseases/dystonia)
• [ALS](/diseases/amyotrophic-lateral-sclerosis)
• [Ion Channelopathies](/mechanisms/ion-channelopathies)
• [Basal Ganglia Circuitry](/mechanisms/basal-ganglia-circuitry)
• [Neuronal Excitability](/mechanisms/neuronal-excitability)

See Also

• [ANO3 Gene](/genes/ano3)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Ion Channelopathies](/mechanisms/ion-channelopathies)
• [Dystonia Mechanisms](/mechanisms/dystonia)

External Links

• [UniProt: Q8N8Y2](https://www.uniprot.org/uniprot/Q8N8Y2)
• [AlphaFold Structure](https://alphafold.ebi.ac.uk/entry/Q8N8Y2)
• [GeneCards: ANO3](https://www.genecards.org/cgi-bin/carddisp.pl?gene=ANO3)
• [PubMed: ANO3 neurodegeneration](https://pubmed.ncbi.nlm.nih.gov/?term=ANO3+Parkinson+ALS)

References